FGFR inhibitors and uses thereof

Patent metadata

Field	Value
Publication number	US-12559470-B2
Application number	US-201917275601-A
Country	US
Kind code	B2
Filing date	Sep 12, 2019
Priority date	Sep 13, 2018
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The invention provides novel FGFR inhibitors based on the pyridinylpyrimidine. The invention includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.

First claim

What is claimed is:

1 . A compound of Formula (I):

or an optically pure stereoisomer or pharmaceutically acceptable salt thereof,
wherein:
each instance of X is independently CH or N;
each instance of R 1 is independently halogen or methoxy;
the number of R 1 substituents is 1, 2, 3 or 4;
each instance of R 2 is independently selected from the group consisting of hydrogen, methyl, amino, propargyloxy,

and the number of R 2 substituents is 1 or 2.

2 . The compound of claim 1 , wherein the compound is:

or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , wherein the compound is selected from 6-(2-((2,6-dichloro-3,5-dimethoxyphenyl)amino)pyridin-3-yl)-N-(4-(4-ethylpiperazin-1-yl)phenyl)pyrimidin-4-amine or N-(2-((6-(2-((2,6-dichloro-3,5-dimethoxyphenyl)amino)pyridin-3-yl)pyrimidin-4-yl)amino)-3-methylphenyl) acrylamide.

4 . The compound of claim 1 , wherein the compound inhibits a fibroblast growth factor receptor (FGFR).

5 . The compound of claim 4 , wherein the compound inhibits FGFR4.

6 . A method for treating a cancer associated with a FGFR signaling pathway in a subject in need thereof comprising administering a compound of Formula (I) or an optically pure stereoisomer or pharmaceutically acceptable salt thereof to the subject,

wherein:
each instance of X is independently CH or N;
each instance of R 1 is independently halogen or methoxy;
the number of R 1 substituents is 1, 2, 3 or 4;
each instance of R 2 is independently selected from hydrogen, methyl, amino, propargyloxy,

and the number of R 2 substituents is 1 or 2,
thereby treating the cancer.

7 . The method of claim 6 , wherein the compound is:

or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof.

8 . The method of claim 6 , wherein the cancer is selected from the group consisting of breast, lung, bladder, prostate, ovarian, endometrial, rhabdomyosarcoma, liver and gastric.

9 . The method of claim 6 , wherein the compound inhibits an FGFR.

10 . The method of claim 9 , wherein the compound inhibits FGFR4.

11 . The method of claim 6 , wherein the compound targets amino acid residue 484 of SEQ ID NO: 52, amino acid residue 512 of SEQ ID NO: 56, or amino acid residue 552 of SEQ ID NO: 50 or 54.

12 . The method of claim 6 , further comprising administering a chemotherapeutic agent.

13 . The method of claim 12 , wherein the compound is administered prior to, simultaneously with or following the administration of the chemotherapeutic agent.

14 . A pharmaceutical composition comprising a compound of Formula (I) or an optically pure stereoisomer or pharmaceutically acceptable salt and a pharmaceutically acceptable carrier,

wherein:
each instance of X is independently CH or N;
each instance of R 1 is independently halogen or methoxy;
the number of R 1 substituents is 1, 2, 3 or 4;
each instance of R 2 is independently selected from hydrogen, methyl, amino, propargyloxy,

and the number of R 2 substituents is 1 or 2.

15 . The pharmaceutical composition of claim 14 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

16 . A method of inhibiting a kinase activity comprising contacting a cell with a compound of Formula (I) or an optically pure stereoisomer or pharmaceutically acceptable salt,

wherein:
each instance of X is independently CH or N;
each instance of R 1 is independently halogen or methoxy;
the number of R 1 substituents is 1, 2, 3 or 4;
each instance of R 2 is independently selected from hydrogen, methyl, amino, propargyloxy,

and the number of R 2 substituents is 1 or 2,
thereby inhibiting the kinase activity.

17 . The method of claim 16 , wherein the compound is:

or an optically pure stereoisomer or a pharmaceutically acceptable salt thereof.

18 . The method of claim 16 , wherein the kinase is selected from the group consisting of Anaplastic lymphoma kinase (ALK), Epidermal growth factor receptor (EGFR), Ephrin type-3 receptor 3 (EPH-B3), Focal adhesion kinase (FAK), Fibroblast growth factor receptor 1 (FGFR1), Fibroblast growth factor receptor 2 (FGFR2), Fibroblast growth factor receptor 3 (FGFR3), Fibroblast growth factor receptor 4 (FGFR4), Mast/stem cell growth factor receptor (SCFR or KIT), Mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), Hepatocyte growth factor receptor (HGFR or MET), Platelet-derived growth factor receptor alpha (PDGFRA), Platelet-derived growth factor receptor beta (PDGFRB),Proto-oncogene tyrosine kinase receptor (RET), Proto-oncogene tyrosine-protein kinase (ROS) and Tyrosine-protein kinase receptor (TYRO 3).

19 . The method of claim 18 , wherein the kinase is FGFR1, FGFR2, FGFR3 and/or FGFR4.

20 . The method of claim 19 , wherein the kinase is FGFR4.

21 . The method of claim 16 , wherein the cell is a cancer cell.

22 . The method of claim 21 , wherein the cancer cell is a breast, lung, bladder, prostate, ovarian, endometrial, rhabdomyosarcoma, liver or gastric cancer cell.

23 . A method of treating a cancer associated with a FGFR signaling pathway comprising administering to a subject in need thereof a compound of claim 1 .

Assignees

• Univ Southern California

Inventors

• Zhang Chao
• Miranda Renata Rezende
• Ni Feng
• Carpten John

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title